Skip to main content
Top
Published in: Breast Cancer Research and Treatment 1/2021

01-02-2021 | Fluorescence in Situ Hybridization | Preclinical study

HER2 fluorescent in situ hybridization signal degradation: a 10-year retrospective study

Authors: Jessie M. Wu, Andrey-Ann Galibois, Neha Seebocus, Anupam Apu, Marta Hnatovska, Annie Wilson, Teresa Shortill, Gulisa Turashvili

Published in: Breast Cancer Research and Treatment | Issue 1/2021

Login to get access

Abstract

Context

Fluorescence in situ hybridization (FISH) analysis is recommended for invasive breast carcinomas with equivocal (2+) immunohistochemical expression of human epidermal growth factor receptor 2 (HER2). However, existing guidelines for the retention and storage requirements for HER2 FISH slides vary widely among countries and laboratories.

Objective

To determine the degradation rate of HER2 FISH signals, and the optimal retention time and storage conditions for HER2 FISH slides.

Design

Dual-probe HER2 FISH slides from March 2009 to June 2019 were retrieved from the archive to assess the presence, intensity and quantity of the green chromosome enumeration probe 17 (CEP 17) and orange HER2 signals. Per the institutional policy, FISH slides are placed in slide boxes and stored in − 80 °C freezers for up to 4 years, whereas older slides are stored at room temperature.

Results

After excluding HER2 FISH slides that were deemed uninterpretable due to technical issues, a total of 6255 slides were assessed. Slides from 2009 to 2014 were stored at room temperature, while slides from 2015 to 2019 were stored in − 80 °C freezers. Slides stored in freezers showed retention of both the green and the orange signals. Slide stored at room temperature demonstrated significant decrease in the signal retention rate and the loss of signal did not progress in a linear fashion. The CEP17 signal was quenched much faster than the HER2 signal.

Conclusion

Our study is the first to demonstrate HER2 FISH signal degradation with time and slide storage conditions. Storing HER2 FISH slides in a –80 °C freezer allows for retention of both HER2 and CEP17 signals. At room temperature, the signals start to degrade with CEP17 signals lost at a faster rate. The results of the study may be used in official guidelines for storage conditions and retention time for HER2 FISH slides.
Literature
1.
go back to reference Russnes HG, Lingjærde OC, Børresen-Dale AL, Caldas C (2017) Breast Cancer molecular stratification: from intrinsic subtypes to integrative clusters. Am J Pathol 187(10):2152–2162CrossRef Russnes HG, Lingjærde OC, Børresen-Dale AL, Caldas C (2017) Breast Cancer molecular stratification: from intrinsic subtypes to integrative clusters. Am J Pathol 187(10):2152–2162CrossRef
2.
go back to reference Howlader N, Cronin KA, Kurian AW, Andridge R (2018) Differences in breast Cancer survival by molecular subtypes in the United States. Cancer Epidemiol Biomark Prev 27(6):619–626CrossRef Howlader N, Cronin KA, Kurian AW, Andridge R (2018) Differences in breast Cancer survival by molecular subtypes in the United States. Cancer Epidemiol Biomark Prev 27(6):619–626CrossRef
3.
go back to reference Howlader N, Altekruse SF, Li CI et al (2014) US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status. J Natl Cancer Inst 106(5) Howlader N, Altekruse SF, Li CI et al (2014) US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status. J Natl Cancer Inst 106(5)
4.
go back to reference Curigliano G, Burstein HJ, Winer EP et al (2017) De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen international expert consensus conference on the primary therapy of early breast Cancer 2017. Ann Oncol 28(8):1700–1712CrossRef Curigliano G, Burstein HJ, Winer EP et al (2017) De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen international expert consensus conference on the primary therapy of early breast Cancer 2017. Ann Oncol 28(8):1700–1712CrossRef
5.
go back to reference Wolf-Yadlin A, Kumar N, Zhang Y et al (2006) Effects of HER2 overexpression on cell signaling networks governing proliferation and migration. Mol Syst Biol 2:54CrossRef Wolf-Yadlin A, Kumar N, Zhang Y et al (2006) Effects of HER2 overexpression on cell signaling networks governing proliferation and migration. Mol Syst Biol 2:54CrossRef
6.
go back to reference Slamon DJ, Godolphin W, Jones LA et al (1989) Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244(4905):707–712CrossRef Slamon DJ, Godolphin W, Jones LA et al (1989) Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244(4905):707–712CrossRef
7.
go back to reference Jerusalem G, Lancellotti P, Kim SB (2019) HER2+ breast cancer treatment and cardiotoxicity: monitoring and management. Breast Cancer Res Treat 177(2):237–250CrossRef Jerusalem G, Lancellotti P, Kim SB (2019) HER2+ breast cancer treatment and cardiotoxicity: monitoring and management. Breast Cancer Res Treat 177(2):237–250CrossRef
8.
go back to reference Waks AG, Winer EP (2019) Breast Cancer treatment: a review. JAMA 321(3):288–300CrossRef Waks AG, Winer EP (2019) Breast Cancer treatment: a review. JAMA 321(3):288–300CrossRef
9.
go back to reference Fitzgibbons PL, Bartley AN, Connolly JL (2020) Template for reporting results of biomarker testing of specimens from patients with carcinoma of the breast. 1.4.0.0 ed. College Am Pathol 15 Fitzgibbons PL, Bartley AN, Connolly JL (2020) Template for reporting results of biomarker testing of specimens from patients with carcinoma of the breast. 1.4.0.0 ed. College Am Pathol 15
10.
go back to reference Wolff AC, Hammond MEH, Allison KH et al (2018) Human epidermal growth factor receptor 2 testing in breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update. J Clin Oncol 36(20):2105–2122CrossRef Wolff AC, Hammond MEH, Allison KH et al (2018) Human epidermal growth factor receptor 2 testing in breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update. J Clin Oncol 36(20):2105–2122CrossRef
11.
go back to reference Varga Z, Noske A, Ramach C, Padberg B, Moch H (2013) Assessment of HER2 status in breast cancer: overall positivity rate and accuracy by fluorescence in situ hybridization and immunohistochemistry in a single institution over 12 years: a quality control study. BMC Cancer 13:615CrossRef Varga Z, Noske A, Ramach C, Padberg B, Moch H (2013) Assessment of HER2 status in breast cancer: overall positivity rate and accuracy by fluorescence in situ hybridization and immunohistochemistry in a single institution over 12 years: a quality control study. BMC Cancer 13:615CrossRef
12.
go back to reference Pathologists TCoA. College of American Pathologists (CAP) Retention of Laboratory Records and Materials: College of American Pathologists; 2010:1–3 Pathologists TCoA. College of American Pathologists (CAP) Retention of Laboratory Records and Materials: College of American Pathologists; 2010:1–3
13.
go back to reference The retention and storage of pathological records and specimens. Guidance from The Royal College of Pathologists and the Institute of Biomedical Science. 5th ed: The Royal College of Pathologists and the Institute of Biomedical Science; 2015:1–59 The retention and storage of pathological records and specimens. Guidance from The Royal College of Pathologists and the Institute of Biomedical Science. 5th ed: The Royal College of Pathologists and the Institute of Biomedical Science; 2015:1–59
14.
go back to reference Council NPAA. Requirements for the Retention of Laboratory Records and Diagnostic Material. 7th ed; 2018:1–35 Council NPAA. Requirements for the Retention of Laboratory Records and Diagnostic Material. 7th ed; 2018:1–35
15.
go back to reference Krishnamurti U, Silverman JF (2014) HER2 in breast cancer: a review and update. Adv Anat Pathol 21(2):100–107CrossRef Krishnamurti U, Silverman JF (2014) HER2 in breast cancer: a review and update. Adv Anat Pathol 21(2):100–107CrossRef
16.
go back to reference Carlson RW, Moench SJ, Hammond ME et al (2006) HER2 testing in breast cancer: NCCN task force report and recommendations. J Natl Compr Cancer Netw 4(Suppl 3) S1-22; quiz S23-4 Carlson RW, Moench SJ, Hammond ME et al (2006) HER2 testing in breast cancer: NCCN task force report and recommendations. J Natl Compr Cancer Netw 4(Suppl 3) S1-22; quiz S23-4
17.
go back to reference Bethune GC, Pettit AS (2017) Veldhuijzen van Zanten D, Barnes PJ. Well-differentiated invasive breast cancers with equivocal HER2 immunohistochemistry: what is the yield of routine reflex in-situ hybridization testing? Histopathology 70(6):966–974CrossRef Bethune GC, Pettit AS (2017) Veldhuijzen van Zanten D, Barnes PJ. Well-differentiated invasive breast cancers with equivocal HER2 immunohistochemistry: what is the yield of routine reflex in-situ hybridization testing? Histopathology 70(6):966–974CrossRef
18.
go back to reference Griffin BB, Pincus JL, Siziopikou KP, Blanco LZ (2018) Double-equivocal HER2 invasive breast carcinomas: institutional experience and review of literature. Arch Pathol Lab Med 142(12):1511–1516CrossRef Griffin BB, Pincus JL, Siziopikou KP, Blanco LZ (2018) Double-equivocal HER2 invasive breast carcinomas: institutional experience and review of literature. Arch Pathol Lab Med 142(12):1511–1516CrossRef
19.
go back to reference Bartlett JM, Campbell FM, Ibrahim M et al (2011) A UK NEQAS ISH multicenter ring study using the Ventana HER2 dual-color ISH assay. Am J Clin Pathol 135(1):157–162CrossRef Bartlett JM, Campbell FM, Ibrahim M et al (2011) A UK NEQAS ISH multicenter ring study using the Ventana HER2 dual-color ISH assay. Am J Clin Pathol 135(1):157–162CrossRef
20.
go back to reference Wakai S, Shibuki Y, Yokozawa K et al (2014) Recycling and long-term storage of fluorescence in situ hybridization slides. Am J Clin Pathol 141(3):374–380CrossRef Wakai S, Shibuki Y, Yokozawa K et al (2014) Recycling and long-term storage of fluorescence in situ hybridization slides. Am J Clin Pathol 141(3):374–380CrossRef
21.
go back to reference Radziuviene G, Rasmusson A, Augulis R et al (2017) Automated image analysis of HER2 fluorescence in situ hybridization to refine definitions of genetic heterogeneity in breast Cancer tissue. Biomed Res Int 2017:2321916CrossRef Radziuviene G, Rasmusson A, Augulis R et al (2017) Automated image analysis of HER2 fluorescence in situ hybridization to refine definitions of genetic heterogeneity in breast Cancer tissue. Biomed Res Int 2017:2321916CrossRef
22.
go back to reference van der Logt EM, Kuperus DA, van Setten JW et al (2015) Fully automated fluorescent in situ hybridization (FISH) staining and digital analysis of HER2 in breast cancer: a validation study. PLoS One 10(4):e0123201CrossRef van der Logt EM, Kuperus DA, van Setten JW et al (2015) Fully automated fluorescent in situ hybridization (FISH) staining and digital analysis of HER2 in breast cancer: a validation study. PLoS One 10(4):e0123201CrossRef
23.
go back to reference Holten-Rossing H, Møller Talman ML, Kristensson M, Vainer B (2015) Optimizing HER2 assessment in breast cancer: application of automated image analysis. Breast Cancer Res Treat 152(2):367–375CrossRef Holten-Rossing H, Møller Talman ML, Kristensson M, Vainer B (2015) Optimizing HER2 assessment in breast cancer: application of automated image analysis. Breast Cancer Res Treat 152(2):367–375CrossRef
24.
go back to reference Kornstein MJ, Byrne SP (2007) The medicolegal aspect of error in pathology: a search of jury verdicts and settlements. Arch Pathol Lab Med 131(4):615–618CrossRef Kornstein MJ, Byrne SP (2007) The medicolegal aspect of error in pathology: a search of jury verdicts and settlements. Arch Pathol Lab Med 131(4):615–618CrossRef
25.
go back to reference Troxel DB (2012) Trends in pathology malpractice claims. Am J Surg Pathol 36(1):e1–e5CrossRef Troxel DB (2012) Trends in pathology malpractice claims. Am J Surg Pathol 36(1):e1–e5CrossRef
26.
go back to reference Zylstra S, D'Orsi CJ, Ricci BA et al (2001) Defense of breast cancer malpractice claims. Breast J 7(2):76–90CrossRef Zylstra S, D'Orsi CJ, Ricci BA et al (2001) Defense of breast cancer malpractice claims. Breast J 7(2):76–90CrossRef
27.
go back to reference Murphy BL, Ray-Zack MD, Reddy PN et al (2018) Breast Cancer litigation in the 21st century. Ann Surg Oncol 25(10):2939–2947CrossRef Murphy BL, Ray-Zack MD, Reddy PN et al (2018) Breast Cancer litigation in the 21st century. Ann Surg Oncol 25(10):2939–2947CrossRef
28.
go back to reference Peterson JE (2019) Survey of medical malpractice cases and settlements with pathology or laboratory standard of care issues. Semin Diagn Pathol 36(5):366–371CrossRef Peterson JE (2019) Survey of medical malpractice cases and settlements with pathology or laboratory standard of care issues. Semin Diagn Pathol 36(5):366–371CrossRef
Metadata
Title
HER2 fluorescent in situ hybridization signal degradation: a 10-year retrospective study
Authors
Jessie M. Wu
Andrey-Ann Galibois
Neha Seebocus
Anupam Apu
Marta Hnatovska
Annie Wilson
Teresa Shortill
Gulisa Turashvili
Publication date
01-02-2021
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 1/2021
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-020-06048-9

Other articles of this Issue 1/2021

Breast Cancer Research and Treatment 1/2021 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine